Your ADHD Is an Energy Problem
This article makes the case that ADHD is, at its functional core, a brain energy production deficit — not purely a developmental wiring disorder.
1 The foundational PET evidence
In 1990, Zametkin and colleagues at the NIH published a PET study in the New England Journal of Medicine. They put 25 adults with ADHD and 50 matched controls into a PET scanner and measured cerebral glucose metabolism — how much fuel the brain was actually burning.
The result: 8.1% lower global cerebral glucose metabolism in ADHD adults. Significant hypometabolism in 30 of 60 brain regions examined. The largest reductions were in the premotor cortex and superior prefrontal cortex — the regions responsible for sustained attention, planning, and impulse control (Zametkin et al. 1990).
Important caveat: a 1993 follow-up by the same group in adolescents did not replicate the global finding after correcting for brain size, and subsequent PET literature has been mixed. The hypometabolism signal is real but its interpretation — energy supply failure vs. reduced demand from less active circuits — remains debated.
Under the energy framing, the ADHD brain is running its most energy-hungry region on a reduced fuel supply.
2 This wasn’t a one-off finding
A 2025 systematic review pooled 20 cerebral blood flow studies with 1,652 ADHD participants and 580 controls. The core finding: resting-state hypoperfusion — reduced blood flow — in right orbitofrontal gyrus, temporal cortex, basal ganglia, and putamen.
Under the energy interpretation, less blood flow means less oxygen, less glucose, less ATP. An alternative interpretation — that reduced neural activity causes reduced blood flow rather than the reverse — remains possible; the directionality is not fully resolved (Berthier et al. 2025).
Methylphenidate — the most common ADHD medication — normalises striatal, thalamic, and precentral blood flow. It doesn’t fix wiring. Under this model, it restores fuel delivery.
3 Energy failure and neuroinflammation — in the same brain
A 2021 dual-tracer PET study simultaneously imaged two things in 24 drug-naive ADHD adults vs 24 controls:
- Dopamine D1 receptor availability — reduced in the anterior cingulate cortex, correlated with hyperactivity severity
- Microglial activation — increased in the dorsolateral prefrontal cortex and orbitofrontal cortex, correlated with processing speed and attention deficits
The critical finding: these two measures were positively correlated — only in the ADHD group. The more dopamine deficit, the more neuroinflammation (Yokokura et al. 2021).
The same brain shows catecholamine deficit and immune activation. At baseline. Before any illness.
This matters because ME/CFS is characterised by a similar dual finding: catecholamine depletion + neuroinflammation. The NIH deep phenotyping study documented reduced CSF dopamine metabolites in ME/CFS patients (Walitt et al. 2024). Under the energy model, this suggests the ADHD brain may already occupy a milder point on the same metabolic continuum — though shared biomarkers do not prove shared mechanism. The same downstream pattern (low dopamine + inflammation) can arise from different upstream causes.
4 The iron double-deficit
Iron deficiency is common in ADHD — and it compounds the energy problem through a dual mechanism:
Mechanism 1: Iron is a required cofactor for tyrosine hydroxylase — the rate-limiting enzyme in dopamine and norepinephrine synthesis. Low iron means less neurotransmitter production.
Mechanism 2: Iron is also a required cofactor for mitochondrial complex I and complex II — the core of cellular energy production. Low iron means less ATP.
One mineral. Two critical deficits. Impaired neurotransmitter production AND reduced energy output.
Recommended ferritin thresholds per neurodevelopmental guidelines: below 30 ng/mL is suboptimal for ADHD; below 50 ng/mL for ASD-related sleep phenotypes. Standard lab “normal” ranges (typically >12 ng/mL) may miss functionally significant deficits (DelRosso, Estrada Chaverri, and Ceballos Fuentes 2026).
5 The BH4 bottleneck
Tetrahydrobiopterin (BH4) is the rate-limiting cofactor for: - Tyrosine hydroxylase → dopamine and norepinephrine synthesis - Tryptophan hydroxylase → serotonin synthesis - All three NOS isoforms → nitric oxide synthesis (vascular tone regulation)
A single cofactor deficit simultaneously impairs three neurotransmitter systems AND cerebral blood flow regulation (Williams et al. 2025).
A genetic variant — GCH1 rs841 — reduces BH4 production. It is homozygous in approximately 4% of the population. It has been associated with ADHD, autism, depression, anxiety, and PMDD. Five case reports showed ADHD improvement with low-dose BH4 supplementation (0.088–0.292 mg/kg/day) (Williams et al. 2025).
Inflammatory cytokines paradoxically increase BH4 synthesis but accelerate its oxidation — resulting in net monoamine depletion during illness (Fanet et al. 2021). This creates a mechanistic bridge between infection and attention failure.
6 Is ADHD really “developmental”?
The conventional view — supported by decades of genetic, neuroimaging, and longitudinal research — is that ADHD is a neurodevelopmental disorder. The brain is wired differently from early life.
One challenge to this view: the Dunedin birth cohort study followed 1,037 people from birth to age 38 with 95% retention:
- 90% of adults meeting ADHD criteria at age 38 had NO childhood ADHD
- Only 5% of childhood ADHD cases still met criteria at 38
- Adult-onset group showed no neuropsychological deficits in childhood AND no polygenic risk for childhood ADHD
- Childhood and adult ADHD were “virtually non-overlapping sets”
If adult ADHD isn’t developmental, what is it? One possibility: acquired catecholamine insufficiency — arising from stress, chronic inflammation, hormonal changes, or infection (Moffitt et al. 2015).
This interpretation remains contested — Faraone & Biederman (2016) argued the adult-onset cases may reflect subthreshold childhood symptoms, diagnostic threshold effects, or comorbid conditions mimicking ADHD. But it opens the door to a question with implications: can ADHD symptoms be acquired through metabolic disruption?
7 Every effective treatment works through energy
| Treatment | Mechanism (energy framing) |
|---|---|
| Stimulants (methylphenidate, amphetamines) | Increase catecholamine availability → more signal per unit of neural energy |
| Exercise | Increases cerebral blood flow, BDNF, acute catecholamine release (note: exercise recommendations require critical modification in ME/CFS — graded exercise therapy is contraindicated per NICE 2021) |
| Sleep | Restores mitochondrial function; sleep deprivation mimics ADHD |
| Iron supplementation | Restores TH cofactor + complex I/II function |
| Caffeine | Blocks adenosine → temporarily increases effective energy budget |
Under the energy lens, none of these fix “wiring” — all increase energy availability or reduce energy demand at the prefrontal synapse. Mitochondrial dysfunction has been identified as a core component of ADHD pathophysiology, further supporting the energy deficit model (Almutairi et al. 2024). Under the standard neurotransmitter model, these same treatments work by restoring dopaminergic/noradrenergic signaling. Both framings predict the same treatment responses; distinguishing them requires measuring whether energy supply or neurotransmitter signaling is the primary deficit.
Note: This table presents mechanistic framings derived from the research literature, not clinical recommendations. Treatment decisions should be made with a qualified clinician.
8 The reframe
ADHD is not a character flaw. It is not a discipline problem. It may not even be, in all cases, a fixed developmental trait.
It is what happens when the brain’s most metabolically demanding region — the prefrontal cortex — cannot get enough fuel to sustain its functions.
Sometimes the fuel supply is genetically small. Sometimes it is depleted by inflammation, iron deficiency, or BH4 oxidation. Sometimes it is reduced by chronic hypoperfusion.
The downstream symptom is the same: attention failure, executive dysfunction, impulsivity. Because the prefrontal cortex fails first when energy runs low — every time, in every context.
And that has implications far beyond attention. Under this model, the same energy system that fails mildly in ADHD fails catastrophically in ME/CFS. The next article in this series explains why ADHD patients develop chronic disabling fatigue at twice the population rate.
9 Limitations and alternative interpretations
This article presents ONE interpretive lens — the energy/metabolic framing. Key alternatives that the reader should weigh:
- Cause vs consequence: Reduced glucose metabolism may reflect reduced neural activity (effect of different wiring), not insufficient energy supply (cause of dysfunction). If so, ADHD remains a developmental connectivity disorder and the metabolic findings are downstream signatures.
- Genetic pleiotropy: ADHD and ME/CFS may share genetic risk variants that independently produce both conditions, without one causing the other through a metabolic pathway.
- Inflammation as simpler explanation: Chronic low-grade inflammation (as shown by IL-6 in the ALSPAC data) may directly cause both neurodivergent traits and fatigue vulnerability, without requiring a “metabolic reserve” concept.
The energy framing generates testable predictions distinct from these alternatives — particularly around whether correcting modifiable energy deficits (iron, BH4, perfusion) prevents ME/CFS onset. Until those tests are done, the model remains a hypothesis, not an established mechanism.
Part 1 of a series on the energy biology linking ADHD, autism, and ME/CFS.